<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00469261</url>
  </required_header>
  <id_info>
    <org_study_id>TIP-TOP</org_study_id>
    <nct_id>NCT00469261</nct_id>
  </id_info>
  <brief_title>Tetracycline (Doxycycline) and Post Myocardial Infarction Remodeling</brief_title>
  <acronym>TIPTOP</acronym>
  <official_title>Tetracycline (Doxycycline) In Patients With Large Acute Myocardial Infarction TO Prevent Left Ventricular Remodeling. TIPTOP Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Careggi Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Careggi Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to assess the efficacy of an antibiotic treatment with tetracycline
      (doxycycline) in the early stage of large reperfused acute myocardial infarction (AMI), in
      preventing left ventricular (LV) remodeling.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A myocardial interstitial matrix, that provides structural support and integrity to the
      myocardium, is a key element to determine post infarction left ventricular remodeling (LVR).

      The metalloproteinases (MMPs), an enzymatic system secreted in the extracellular medium by
      macrophages, has been shown to be able to degrade the most important extracellular matrix
      components.

      Various animal experimental models have demonstrated that MMP specific inhibition in the
      first phase of myocardial infarction is able to contrast LVR. Doxycycline, a member of the
      tetracyclines, has been shown to block various inflammation mediators and to attenuate MMP-2
      and MMP-9 expression and activity at a sub-antimicrobial dosage. Some experimental studies on
      rat models have suggested an anti-remodeling effect of doxycycline in myocardial infarction.

      In the present study we want to evaluate if a treatment with doxycycline (100 mg b.i.d.) in
      the first seven days after a reperfused large (ejection fraction less than 40%) acute
      myocardial infarction, is effective in preventing six-month LVR.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2007</start_date>
  <completion_date type="Actual">August 2011</completion_date>
  <primary_completion_date type="Actual">August 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction of LV dilation (six months versus baseline LV end-diastolic volume index by 2D-echocardiogram [echo]) more than 50% in the treated group in comparison to the placebo group</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the time course of MMPs and their inhibitors in relation to left ventricular remodeling</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">110</enrollment>
  <condition>Myocardial Infarction</condition>
  <condition>Left Ventricular Remodeling</condition>
  <arm_group>
    <arm_group_label>Doxycycline</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Active drug 100 mg bid for seven days in pts with AMI treated with Primary PCI and current medical therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard Therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Pts with AMI treated with Primary PCI and current medical therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxycycline</intervention_name>
    <description>Doxycycline 100 mg bid for seven days after enrollment</description>
    <arm_group_label>Doxycycline</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Current medical therapy for AMI</intervention_name>
    <description>Current medical therapy for AMI</description>
    <arm_group_label>Standard Therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Acute myocardial infarction

          -  Left ventricular ejection fraction less than 40%

        Exclusion Criteria:

          -  No written consensus

          -  Allergy to tetracycline

          -  Mechanical complication of AMI

          -  Previous myocardial infarction

          -  Valvular and/or myocardiopathy known or suspected

          -  Renal failure (creatinine above 2 mg/dL)

          -  Connective tissue disease

          -  Pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Giampaolo Cerisano, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Careggi Hospital, Florence, Italy</affiliation>
  </overall_official>
  <overall_official>
    <last_name>David Antoniucci, MD</last_name>
    <role>Study Director</role>
    <affiliation>Careggi Hospital, Florence, Italy</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Piergiovanni Buonamici, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Careggi Hospital, Florence, Italy</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Emilio V Dovellini, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Careggi Hospital, Florence, Italy</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alberto Santini, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Careggi Hospital, Florence, Italy</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Umberto Signorini, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Careggi Hospital, Florence, Italy</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nazario Carrabba, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Careggi Hospital, Florence, Italy</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Paolo D Pucci, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Careggi Hospital, Florence, Italy</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Renato Valenti, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Careggi Hospital , Florence, Italy</affiliation>
  </overall_official>
  <removed_countries>
    <country>Italy</country>
  </removed_countries>
  <verification_date>September 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 3, 2007</study_first_submitted>
  <study_first_submitted_qc>May 3, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 4, 2007</study_first_posted>
  <last_update_submitted>September 24, 2012</last_update_submitted>
  <last_update_submitted_qc>September 24, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 25, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Careggi Hospital</investigator_affiliation>
    <investigator_full_name>David Antoniucci</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Myocardial infarction</keyword>
  <keyword>Ventricular remodeling</keyword>
  <keyword>Matrix metalloproteinases</keyword>
  <keyword>Doxycycline</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Ventricular Remodeling</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Doxycycline</mesh_term>
    <mesh_term>Tetracycline</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

